RecruitingNCT07263178

A Study of Second- and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer.

A Multi-center, Prospective, Observational Study to Assess the Treatment Patterns and Prognosis of Second and Later-line Palliative Chemotherapy in Patients With Metastatic Colorectal Cancer Who Failed First-line Palliative Chemotherapy

Sponsor

Boryung Pharmaceutical Co., Ltd

Enrollment

1,000 participants

Start Date

Nov 7, 2025

Study Type

OBSERVATIONAL

Conditions

Metastatic Colorectal Cancer

Summary

This study aims to comprehensively identify the various treatment patterns of second- or subsequent-line palliative chemotherapy used in patients with metastatic colorectal cancer who have experienced failure of first-line palliative chemotherapy and to evaluate the prognosis of each treatment.

Eligibility

Min Age: 19 Years

Inclusion Criteria4

Patients who have signed the informed consent after receiving information about the purpose and method of this study.
Patients with histologically and radiologically confirmed metastatic colorectal cancer (colorectal cancer) who have evaluable (measurable) lesions.
Patients scheduled to receive their first second-line palliative chemotherapy following failure of first-line palliative chemotherapy (including those who relapse during or within 6 months after completion of postoperative adjuvant therapy, necessitating palliative chemotherapy).
Patients who understand the research, are cooperative in the research process, and are deemed capable of participating until the completion date.

Exclusion Criteria3

Female patients who are pregnant, have childbearing potential, or are breastfeeding.
Has received an investigational product within 4 weeks from the study enrollment or has plans to participate in another clinical trial during the participation of this study.
Other subjects who are considered inappropriate to participate in this study by the judgment of the investigator.

Interventions

DRUGSecond and later-line palliative chemotherapy

As this is a non-interventional study designed to collect data as part of routine clinical practice, the selection and dosage of medication, treatment period, and whether or not to change it are all based on the clinician's judgment

Locations(1)

Samsung Medical Center

Seoul, South Korea

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07263178

Related Trials

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

NCT0465706879 locations

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

NCT0682046341 locations

Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed Therapy

NCT059859541 location

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

NCT061494811 location

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

NCT0707963113 locations